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ABSTRACT
Background Lack of evidence-based data on the
spectrum of cardiovascular disease (CVD) in pregnancy
or in the postpartum period, as well as on maternal and
fetal outcome, provides challenges for treating
physicians, particularly in areas of low resources. The
objectives of this study were to investigate the spectrum
of disease, mode of presentation and maternal and fetal
outcome of patients referred to a dedicated Cardiac
Disease and Maternity Clinic (CDM).
Methods The prospective cohort study was conducted
at a single tertiary care centre in South Africa. Two
hundred and twenty-ﬁve women presenting with CVD in
pregnancy, or within 6 months postpartum, were studied
over a period of 2 years. Clinical assessment,
echocardiography and laboratory tests were performed at
baseline and follow-up visits. Prepartum, peripartum and
postpartum complications were grouped into cardiac,
neonatal and obstetric events.
Results Ethnicity was black African (45%), mixed
ethnicity (32%), white (15%), Indian/others (8%) and
12% were HIV positive. Of the 225 consecutive women
(mean age 28.8±6.4), 196 (86.7%) presented prepartum
and 73 in modiﬁed WHO class I. The 152 women
presenting in a higher risk group (modiﬁed WHO class
II–IV) were offered close follow-up at the CDM clinic and
were diagnosed with congenital heart disease (32%, 15
operated previously), valvular heart disease (26%, 15
operated previously), cardiomyopathy (27%) and other
(15%). Women presenting with symptoms of CVD or heart
failure postpartum (n=30) presented in a higher New York
Heart Association, had higher heart rates (p<0.001) and
NTproBNP levels (p<0.0005). Of the 152 patients, 9 (6%)
died within the 6-month follow-up period. Eight of the
nine patients died >42 days postpartum. Perinatal death
occurred in 1/152 (0.7%)—translating to a perinatal
mortality rate of 7/1000 live births.
Conclusions Disease patterns were markedly different to
that seen in the developed world. However, joint obstetric–
cardiac care in the low-resource cohort was associated with
excellent survival outcome rates of pregnant mothers (even
with complex diseases) and their offspring and was similar
to that seen in the western world. Mortality typically
occurred in the postpartum period, beyond the standard
date of recording maternal death.
INTRODUCTION
There is generally a paucity of data describing car-
diovascular disease (CVD) in women from Africa
or other developing regions. In particular, few data
describe CVD related to pregnancy with its unique
disease patterns and presentations.1 2 This has to
be seen in the context of a general shortage of phy-
sicians in Africa; for example, South Africa has
only 165 registered cardiologists for a population
of 50 million. In April 2010, a dedicated weekly
‘Cardiac Disease and Maternity Clinic (CDM)’ was
established at the Division of Cardiology,
Department of Medicine, Groote Schuur Hospital,
University of Cape Town, to provide multidisciplin-
ary systematic care for women with suspected or
previously known CVD, presenting in pregnancy or
postpartum. In July 2010, a prospective single-
centre study was initiated, which aimed to investi-
gate the spectrum of CVD presenting prepartum or
postpartum, as well as the maternal and fetal
outcome using a comprehensive system of care by a
team of obstetricians, anaesthesiologists and
cardiologists.
METHODS
Study design
Between 1 July 2010 and 30 June 2012, 225 con-
secutive patients with suspected or previously diag-
nosed CVD, including blood pressure and heart
rate, were assessed at ﬁrst visit to the joint cardiac–
obstetric clinic, having been sent there via a referral
algorithm from primary care and secondary care
facilities in Cape Town and from within the tertiary
hospital (ﬁgure 1). Risk stratiﬁcation after hours or
via the emergency room were included and assessed
in the wards or at the next available clinic date.
The study was approved by the Ethics Committee
of the University of Cape Town (HEC ref: 173/
2010).
All patients referred to this clinic were seen
jointly by a senior cardiology and obstetric consult-
ant and physicians from other disciplines, for
example, radiology, endocrinology and anaes-
thetics, were consulted. Patients were managed
jointly throughout their pregnancy and those pre-
senting postpartum were seen once at this clinic
and managed further at the general cardiac clinic or
a dedicated cardiomyopathy clinic, Groote Schuur
Hospital (KS). Patients were booked according to
standard management, which could include a
waiting period of up to 3 months.
Data
Baseline data recorded at the ﬁrst visit included
sociodemographic factors, family history of CVD,
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history of pre-eclampsia or chronic hypertension, HIV status,
onset of symptoms and signs, parity, prior cardiac events, prior
surgery or cardiac interventions and use of medication. In add-
ition, New York Heart Association Functional Class (NYHAFC),
ECG and transthoracic echocardiography (KS) were recorded,
including assessments of left and right ventricular function,
Doppler quantiﬁcation of inﬂow and outﬂow obstruction, quan-
tiﬁcation of valvular regurgitation and systolic pulmonary artery
pressure were measured according to standard practice guide-
lines.3 The EF was calculated according to standard criteria,
usually using M-mode and, in some cases, applying the modiﬁed
Simpson method.3
Patients were stratiﬁed into four risk groups using a modiﬁed
WHO risk classiﬁcation for pregnant women with cardiac
disease. Depending on diagnosis and severity of disease, risk
classiﬁcation ranged from class I (low risk) to class IV (contra-
indication for pregnancy), as recently used in the European
Society of Cardiology (ESC) Guidelines on the management of
CVD during pregnancy.4 Diseases not accounted for by this clas-
siﬁcation were scored by two authors, a cardiologist (KS) and an
obstetrician ( JA). The modiﬁed WHO classiﬁcation has a
prediction value in the management of pregnant women but is
also based on the underlying severity of heart disease; uniform-
ity in the classiﬁcation has been secured by applying this classiﬁ-
cation to both antenatal and postpartum patients.
Poor outcome was as previously deﬁned,5 using a combined
endpoint of death, EF <45% or remaining in NYHA FC III/IV
as the cohort was relatively small.
Patients with a history of CVD (but no symptoms or signs)
and a normal clinical examination, together with absent or
minimal echocardiography changes—such as operated congeni-
tal heart disease (CHD) or a prior history of rheumatic fever
without clinical sequelae—were only seen once and then
referred to secondary-level obstetric care. These patients were
classiﬁed as modiﬁed WHO stage I. As many of those patients
were referred from peripheral hospitals, records were not avail-
able to document maternal and fetal outcomes.
Patients with symptoms, signs or a WHO stage II–IV classiﬁ-
cation had clinical visits during the second trimester
(<28 weeks), third trimester (28–37 weeks), peripartum period
(onset of labour until hospital discharge) and at 6 weeks and
6 months postpartum. The frequency of visits was adapted to
Figure 1 Referral algorithm to joint
Cardiac Maternity Clinic, Groote
Schuur Hospital. BMI, body mass
index; BP, blood pressure; ESC,
European Society of Cardiology; ASD,
atrial septal defect; VSD, ventricular
septal defect; NYHA FC, New York
Heart Association Functional Class;
PPCM, peripartum cardiomyopathy;
RHD, rheumatic heart disease; HT,
hormone therapy; AV, aortic valve.
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the severity of the disease and transport logistics of the patient.
For many women, frequent hospital visits are not affordable.
Mode of delivery, use of tocolytic therapy and perinatal
outcome were obtained from patients, referring physicians and
by examining the obstetric records. Newborns of mothers with
CHD underwent paediatric echocardiography.
Peripartum complications were grouped into cardiac, neonatal
and obstetric events. Cardiac events were deﬁned by (re)admis-
sion for heart failure, symptomatic tachycardia requiring
therapy, arrhythmia, stroke and cardiac death. Neonatal events
were deﬁned as any of the following: premature birth
(<37 weeks gestation), small-for-gestational age birthweight
(<10th centile), respiratory distress syndrome, intraventricular
haemorrhage, fetal death (>20 weeks’ gestation) or neonatal
death (within 28 days after birth). Perinatal mortality rates were
calculated based on the number of fetal deaths and early neo-
natal deaths per 1000 live births. Obstetric events that were
documented included non-cardiac death, pregnancy-induced
hypertension, pre-eclampsia and postpartum haemorrhage
(PPH). PPH was deﬁned as blood loss >500 mL (vaginal deliv-
ery) or >1000 mL (caesarean section), which required transfu-
sion or was accompanied by a drop in haemoglobin >2.0 g/L.
Blood tests
Routine laboratory workup on all patients included a haemoglo-
bin and HIV test. Other blood tests, as determined by the
physician, were performed in certain cases. Plasma was collected
at baseline and, in consenting patients, also postdelivery.
Aliquots were stored at −80°C for future analysis. Plasma
NT-proBNP was measured by electrochemiluminescence
immunoassay (BNP Fragment EIA, BIOMEDICA GRUPPE
gmbHa Co, Vienna, Austria).6
Data collection
Data were entered into a speciﬁcally developed web-based plat-
form for this project, which included uploading of ECGs in PDF
or jpeg format and echo-images as still pictures or in AVI mode.
Statistical analysis
Cardiac, neonatal and obstetric events were analysed separately.
Database management and statistical analyses were performed
with SAS software, V.9.2 statistical program (SAS, Institute,
Cary, North Carolina, USA). Continuous data were expressed as
mean±SD or median (range). Comparison of means and pro-
portions between subgroups at baseline was performed by inde-
pendent t test and χ2 statistics (or Fisher’s exact test where
necessary), respectively, and where data were not normally dis-
tributed, a Wilcoxon rank-sum test was used.
Univariate and stepwise multiple logistic regression analyses
were performed to establish independent predictors of poor
outcome. Signiﬁcance was assumed at a two-sided value of
p<0.05.
Table 1 Baseline maternal characteristics of 225 cohorts presenting in modified WHO I–IV
All patients (n=225) WHO I (n=73) WHO II–IV (n=152) p Value
Age at enrolment (years) 28.6±6.4 28.8±7.0 28.5±6.1 0.97
Ethnicity, n (%)
African or black 101 (45) 23 (32) 79 (52) <0.0001
Mixed 72 (32) 15 (20) 56 (37)
White 34 (15) 19 (26) 15 (10)
Other (Arab, Indian, other) 18 (8) 16 (22) 2 (1)
General medical history, n (%)
Chronic hypertension 12 (5) 2 (3) 10 (7) 0.35
Hypercholesterolaemia 3 (1) 0 (0) 3 (2) 0.55
HIV 38 (12) 2 (3) 36 (24) <0.0001
Syphilis 1 (0.4) 0 (0) 1 (1) 1.00
Tuberculosis 4 (2) 0 (0) 4 (3) 0.31
Clinical history and presentation, n (%)
Previously known CVD 93 (41) 40 (55) 53 (35) 0.006
Previously operated CVD 57 (25) 27 (37) 30 (20) 0.007
NYHA FC I-II 193 (86) 73 (100) 120 (79) <0.0001
NYHA FC III-IV 32 (14) 0 (0) 32 (21)
SBP in mmHg 119±15 118±13 119±16 0.97
DBP in mm Hg 74±11 75±10 74±11 0.53
Heart rate in bpm 86±18 78±12 90±19 <0.0001
Weight in kg 72.1±16.8 72.5±12.5 72.1+18.6 0.30
Obstetric history, n (%)
Gestational age at presentation n=188 n=66 n=122
<12 weeks 7 (4) 3 (5) 4 (3)
12–24 weeks 84 (45) 32 (48) 52 (43) 0.65
>24 weeks 97 (52) 31 (47) 66 (54)
Gravida (median, range) 2 (1–7) 2 (1–6) 2 (1–7) 0.0002
Para (median, range) 1 (0–5) 1 (0–4) 1 (0–5) 0.003
Nulliparous, n (%) 65 (29) 29 (40) 36 (24) 0.02
Twin pregnancies 3 (1) 0 (0) 3 (2) 0.30
A number of women were either not pregnant or presented postpartum. Gestational age at presentation percentages calculated towards 187, 66 and 121, respectively.
CVD, cardiovascular disease; DBP, diastolic blood pressure; NYHA FC, New York Heart Association Functional Class; SBP, systolic blood pressure.
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RESULTS
The characteristics of the 225 patient cohort is shown in table 1.
Black patients presented signiﬁcantly more frequently with
advanced disease (WHO II–IV) compared with other ethnic
groups (p<0.0001). There were signiﬁcant differences in heart
rate, gravidity and parity in patients presenting with a diagnosis
in the modiﬁed WHO class I versus those in class II–IV.
Generally, comorbidity, including HIV infection, was associated
with more severe cardiac disease, measured in terms of WHO
classiﬁcation (p<0.0001). Patients with a high-risk category
deﬁned by modiﬁed WHO class presented with more symptom-
atic disease, deﬁned by the NYHAFC and a higher heart rate
(p<0.0001).
Diagnosis
The diagnosis of women classiﬁed as WHO class I (n=73) fell
into one of four categories: history of rheumatic heart disease
(RHD) or minor RHD lesion (n=16; 22%), minor or operated
CHD with no signiﬁcant residual structural abnormality (n=26;
35%), chronic hypertension with no end-organ damage (n=4;
7%) or they had been referred for other reasons such as history
of palpitations or the need for preconception counselling
(n=27; 36%). Diagnoses of the 152 patients presenting in
WHO class II–IV and needing close follow-up were CHD (32%
—ventricular septum defect n=6; atrial septum defect n=8;
coarctation n=3 and others; only 15 operated previously),
RHD (26%, 15 operated previously) and cardiomyopathy (27%
—11 had idiopathic dilated cardiomyopathy; 21 peripartum car-
diomyopathy (PPCM) and 9 hypertension-related cardiomyop-
athy). Fifteen per cent had other diagnosis such as Takayasu’s
disease (n=4), Marfan’s disease (n=4), ventricular arrhythmias
(n=5), constrictive pericarditis (n=3) and others. None of the
women presented with ischaemic heart disease.
Demographics, medical and obstetric history of patients
presenting in WHO II–IV needing follow-up
Table 2 shows ethnic group/ethnicity deﬁned by language, edu-
cational level, disposable income, general medical history
(including smoking), cardiac and obstetric history for patients
presenting prepartum or postpartum. One hundred and twenty-
two women (80%) presented prepartum with 66 (54%) patients
presenting for the ﬁrst time to our clinic with a gestational age
at entry of >24 weeks. Black patients were represented in a
higher percentage in the postpartum cohort (p=0.009). Patients
in modiﬁed WHO class II–IV had signiﬁcantly higher gravidity
(p=0.0002). Women presenting in the postpartum period
(n=30) presented with more advanced NYHA (p<0.001) and
had a signiﬁcantly higher heart rate (p<0.001) and NTproBNP
(p<0.0001).
Presenting symptoms, laboratory tests, ECG, echocardio-
graphic ﬁndings and medication are shown in table 3. Patients
developing symptoms postpartum presented with signiﬁcantly
larger left ventricular dimensions and with a markedly lower
echocardiography EF (44.7±11.8 vs 54.5±12.4, p<0.003).
Of the women diagnosed with CVD prepartum, 27%
received diuretics, 7.3% beta-blockers and 7.3% warfarin while
pregnant (table 3).
Overall and cardiac outcome
Only one patient of the diagnosed prepartum women had no
postpartum visit. Thus, 142 patients had follow-up data.
Maternal mortality rate was 9/152: 5.92%, 95% CI (2.15%
to 9.65%) within the 6-month postpartum follow-up period.
The diagnoses of women who died were familial and PPCM
(n=7) and two cases of prosthetic valve complications (throm-
bosis and sepsis) (table 4). All patients who died belonged to the
mod WHO class III or IV risk group. Eight of the nine patients
died after 42 days of postpartum. Thirty women had poor
outcome as predeﬁned using a combined endpoint of death, EF
and FC.
Of the women that were diagnosed prepartum, 34% devel-
oped signs and symptoms of heart disease while pregnant,
Table 2 Baseline characteristics: demographics and medical
history modified WHO II–IV
All
patients
(n=152)
Presenting
prepartum
(n=122)
Presenting
postpartum
(n=30)
Age at enrolment (years) 28.5±6.1 28.2±6.2 29.6±5.8
Ethnicity, n (%)
African or black 79 (52) 55 (45) 24 (80)*
Mixed 56 (37) 50 (41) 6 (20)*
White 15 (10) 15 (12) 0 (0)
Other (Arab, Indian, other) 2 (1) 2 (2) 0 (0)
Language, n (%)
Afrikaans 43 (28) 40 (33) 3 (10)
English 33 (22) 29 (24) 4 (13)
isiXhosa 58 (38) 41 (34) 17 (57)
isiZulu 12 (8) 9 (7) 3 (10)
Other 6 (4) 3 (2) 3 (10)
Education level, n (%)
No school 1 (1) 0 (0) 1 (3)
Year 1–7 46 (30) 36 (30) 10 (33)
Year 8–11 92 (61) 73 (60) 19 (63)
Year 12/>Year 12 13 (8) 13 (10) 0
Income per month, n (%) (ZAR)
<300 56 (37) 39 (33) 17 (57)
300–999 38 (25) 31 (26) 7 (23)
1000–9999 54 (36) 48 (40) 6 (20)
≥10 000 2 (1) 2 (2) 0 (0)
General medical history (%)
Chronic hypertension 10 (7) 10 (8) 0 (0)
Hypercholesterolaemia 3 (2) 3 (2) 0 (0)
HIV 36 (24) 26 (21) 10 (33)
Syphilis 1 (1) 1 (1) 0 (0)
Tuberculosis 4 (3) 3 (2) 1 (3)
Family history of CVD 23 (15) 21 (17) 2 (7)
Family history of PPCM/CMO 11 (7) 10 (8) 1 (3)
Heart valve replacement/repair 16 (11) 16 (13) 0 (0)
Obstetric history, n (%)
Gestational age at presentation, women presenting prepartum
12–24 weeks 52 (43) 52 (43) 0
>24 weeks 66 (54) 66 (54) 0
Nulliparous n (%) 36 (24) 32 (26) 4 (13)
Parous n (%) 116 (76) 90 (74) 26 (87)
Social history, n (%)
Smoking
Current 10 (6) 8 (7) 2 (7)
Former 2 (1) 2 (2) 0 (0)
Alcohol use
Current 3 (2) 1 (1) 2 (7)
Former 2 (1) 2 (2) 0 (0)
*p<0.009.
CVD, cardiovascular disease; CMO, cardiomyopathy; PPCM, peripartum
cardiomyopathy.
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leading to admission in 20% of cases. At last follow-up, 11% of
the patients were in NYHA functional class III or IV.
Of the 30 patients diagnosed postpartum, 3 died before their
6-month visit. Of the remaining patients, 44% felt minimally to
moderately better, 12% unchanged, 44% minimally or moder-
ately worse compared with ﬁrst presentation.
Obstetric and fetal outcome
The mean gestational stage was 36.7±4.2 with a signiﬁcantly
longer gestational period in women presenting with antenatal
cardiac disease versus presentation postpartum (p=0.04). There
was a high overall rate of operative delivery with 46 of 152
women (30%) having had a caesarean section. There were no sig-
niﬁcant differences between the different modiﬁed WHO class
disease categories (II–IV) in terms of obstetric outcome. In add-
ition to their structural CVD, 11 patients developed gestational
hypertension while pregnant. Preeclampsia was found in 1:30 nul-
lipara and 1:60 multiparous women (n=3 in this cohort).
Perinatal death occurred in 1/152 (0.66%, 95% CI (0.00 to
1.94)) due to one fetal death, translating to a perinatal mortality
Table 3 Symptoms, examination and medication at presentation for patients in modified WHO II–IV
All patients (n=152) Presenting prepartum (n=122) Presenting postpartum (n=30) p Value
Symptoms and severity of disease, n (%)
Palpitations 64 (42) 54 (44) 10 (33) 0.27
Presyncope/syncope 1 (0) 1 (0) 0 (0) 0.58
Chest pain 5 (3) 4 (3) 1 (3) 1.00
NYHA FC
I/II 120 (79) 108 (89) 12 (40) <0.001
III 32 (21) 14 (11) 18 (60) <0.001
Modified WHO group
II-III 98 (64) 98 (80) 0 (0) <0.001
IV 54 (36) 24 (20) 30 (100) <0.001
Vital signs
Heart rate in bpm 90±19 87±17 103±19 <0.0001
SBP in mm Hg 119±16 121±15 111±17 0.001
DBP in mm Hg 74±11 74±12 74±11 0.79
Physical examination, n (%)
Jugular venous pressure >5 42 (28) 20 (16) 22 (73) <0.001
Crepitations 40 (26) 21 (18) 19 (63) <0.001
Oedema 29 (19) 15 (12) 14 (47) <0.001
Systolic heart murmur 86 (57) 60 (49) 26 (87) <0.001
Diastolic heart murmur 7 (5) 7 (6) 0 (0) 0.17
Laboratory tests
Haemoglobin (g/dL) 11.5±1.9 11.5±1.7 11.4±2.4 0.11
HIV positive 36 (24) 26 (21) 10 (36) 0.17
NTProBNP* (median, range) 629.3 (130–6400) 459.6 (130–4885) 1589.9 (130–6400) <0.0001
Log NTProBNP 6.38±1.04 6.15+0.98 7.16+0.89 <0.0001
ECG, n (%)
Sinus rhythm 127 (83) 103 (84) 24 (86) 0.79
Sinus tachycardia 13 (9) 8 (7) 5 (17) 0.09
Atrial fibrillation 1 (1) 1 (3) 0 (0) 0.34
Echocardiogram
LVEDD (mm) 50.6±8.5 48.6±7.7 58.7±6.5 <0.0001
LVESD (mm) 36.9±10.1 33.4±7.6 50.4±6.9 <0.0001
EF (%) (n=62) 51.1±13.0 54.5±12.4 44.7±11.8 0.003
Medications at baseline visit, n (%)
ACE inhibitor 5 0 5 –
Aldosterone antagonist 1 0 1 –
Aspirin 3 3 0 –
Beta blocker 10 9 1 –
Bromocriptine 5 0 5 –
Calcium channel blocker 7 6 1 –
Digoxin 1 1 0 –
Hydralazine 1 1 0 –
Nitrate 0 0 0 –
Furosemide 34 18 16 –
Thiazide 16 15 1 –
Warfarin 9 9 0 –
*NTproBNP measurements were only performed in 110 patients.
DBP, diastolic blood pressure; LVESD, left ventricle in end-systolic diameter; LVEDD, left ventricle in end-diastolic diameter; NYHA FC, New York Heart Association Functional Class; SBP,
systolic blood pressure; ACE inhibitor, angiotensin-converting-enzyme inhibitor.
Healthcare delivery, economics and global health
Sliwa K, et al. Heart 2014;100:1967–1974. doi:10.1136/heartjnl-2014-306199 1971
group.bmj.com on October 13, 2017 - Published by http://heart.bmj.com/Downloaded from 
of 7/1000 live births. In addition, there were two medically
indicated terminations and two miscarriages.
Mean birth weight for the entire cohort was 2850.8
±552.7 g, with 33/148 born weighing <2500 g and 46/148
born preterm (<37 weeks’ duration).
Of 152 babies, 19 had an Apgar score of <7 at 5 min.
Women presenting with cardiac disease postpartum had a
greater proportion of neonates who had lower Apgar scores
(30% vs 8%; p=0.001). There were no signiﬁcant differences
between modiﬁed WHO groups in terms of neonatal
outcome.
Predictors of poor maternal outcome
In the univariate logistic regression analysis, increased heart rate
(p=0.009), increased log NTproBNP (p=0.001), lower income
(p=0.005), more severe NYHA FC at baseline (class I+II vs III
+IV: p=0.048) and decreased EF (p<0.0001) predicted poor
outcome. In multivariate analysis, only the echocardiography EF
prevailed as an independent predictor of poor outcome
(p<0.0001: OR=0.93 (0.90 to 0.96)), after adjusting for age,
HR, systolic blood pressure, log NTproBNP, income, level of
education, HIV status, WHO class and NYHA FC at baseline.
DISCUSSION
A number of registries on women with heart disease in preg-
nancy have been reported in the past.7–10 However, they are
predominantly from the developed world with a focus on
women presenting with operated CHD.9 10 They, therefore, do
not cover the entire burden of CVD in pregnancy particular to
an African population. This study evaluated the clinical
outcome, based upon a referral algorithm deemed practical and
appropriate for the local clinical service, in which patients often
do not have prediagnosed illness because they have poor access
to healthcare outside of pregnancy and are referred to a tertiary
service only late in their disease due to a lack of awareness of
cardiac symptoms by both patients and primary healthcare
nurses. A weekly clinic with a senior cardiologist and obstetri-
cian allowed speedy assessment of complex cases and
appropriate workup, including evaluation by an anaesthetist
prior to delivery and prenatal evaluation of the fetus.
The study has shown a disease pattern markedly different to
that seen in the developed world with RHD, cardiomyopathies
and CHD, some previously not diagnosed, being major pro-
blems, often complicated by HIV/AIDS as a comorbidity.
The data presented demonstrate a signiﬁcantly higher mater-
nal mortality rate with nine of 152 cases (5.9%) compared with
1% in a recent study performed by ESC.7 Interestingly, most of
the deaths were attributable to different forms of cardiomyop-
athies, with only two being related to complications attributable
to sepsis and thrombosis affecting prosthetic heart valves. These
observations are relevant to the general pattern of maternal
mortality described in South. The conﬁdential inquiry into
maternal death in South Africa reported that, of the 4867 death
reported over 2 years, 14% were due to hypertensive disorders,
with another 8.8% due to medical and surgical conditions.11
The deﬁnitions employed describe maternal death as death
occurring during pregnancy or within 42 days of delivery as it is
international standard.12 The deﬁnition of death within 42 days
applied to our data would have completely underestimated the
number of cardiac deaths related to pregnancy because eight out
of nine deaths would not have been captured. Our data suggest
that care needs to be stepped up covering the postpartum
period with earlier referral to the general cardiac or cardiomy-
opathy clinic and adequate counselling about the risks of future
pregnancy and contraceptive services be provided. Our ﬁndings
are likely to be applicable to other regions where cardiomyop-
athies due to a number of conditions are common.13 14
A recent systematic review of the burden of antenatal heart
disease in South Africa reported a prevalence of heart disease,
ranging from 123 to 943 per 100 000 deliveries with RHD
being the most common abnormality, followed by cardiomyop-
athies.15 The results of the Global Burden of Disease Study
2013 on global, regional and national levels and causes of
maternal mortality during 1990–2013, published in 2014,
reported on an ongoing high maternal mortality in South
Africa, with 171.5/100 000 live births.16 Although substantial
progress has been made, South Africa will not meet the ﬁfth
Table 4 Maternal mortality in women with structural heart disease
Diagnosis
Timing of
presentation
Modified WHO
class
NYHA
class
Age
(years)
EF
(%) When Reason Fetal outcome
PPCM with subsequent
pregnancy
Prepartum IV II 24 45 61 days
postpartum
Sudden death Fetal survival
PPCM Postpartum IV II 32 32 130 days
postpartum
CCF Fetal survival
Rheumatic HD with DVR Prepartum IV I 19 30 50 days
postpartum
Valve
thrombosis
Fetal survival
PPCM Postpartum IV III 24 24 122 days
postpartum
CCF Fetal survival
Familial CMO Prepartum IV II 43 30 44 day
spostpartum
CCF Fetal survival
PPCM Prepartum IV II 32 25 95 days
postpartum
Sudden death Fetal survival
Familial CMO Prepartum IV III 25 26 92 days
postpartum
CCF Fetal survival
PPCM post miscarriage Postpartum IV IV 24 31 150 postpartum CCF Miscarriage 20
weeks
Rheumatic HD with MVR Prepartum IV I 25 60 16 weeks
prepartum
SBE Fetal death
CCF, congestive cardiac failure; CMO, cardiomyopathy; DVR, double valve replacement; HD, heart disease; MVR, mitral valve replacement; NYHA, New York Heart Association; PPCM,
peripartum cardiomyopathy; SBE, subacute bacterial endocardititis.
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Millennium Developmental Goal. Heart disease, chronic hyper-
tension and preeclampsia contributed to more than 20% of
3024 cases with severe maternal outcome in the WHO
Multicountry Survey on maternal and newborn health.17
In addition to the high number of postnatal deaths, our data
showed that 18% of women who survived and attended
follow-up clinics had symptoms that were worse after the preg-
nancy, with 44% having moderate-to-severe disability. There
were no discriminating criteria according to diagnosis that
allowed any prediction of who would become more symptom-
atic, although the EF was signiﬁcantly worse in the cardiomyop-
athy group.
The obstetric outcome for the cohort studied was good.
There were no stillbirths and only one neonatal death. Although
30% of the patients delivered before 37 weeks, the mean gesta-
tional age at delivery fell just short of 37 weeks and the mean
birth weight was 2.85 kg. There was a high rate of obstetric
intervention evident as a 30% caesarean section rate, similar to
the 27% in the Canadian CARPREG study8 and 41% in the
European cohort.7 In addition, one in ﬁve pregnancies required
hospitalisation for cardiac assessment and treatment during the
course of the pregnancy.
The perinatal outcome in an environment of intensive surveil-
lance and management was found to be generally good. This
has to be seen in the context of a high overall perinatal mortal-
ity of 34/1000 live births in South Africa.11
With regards to the clinical service provision, a large propor-
tion of the women studied had RHD due to the sequelae of
group A streptococcal infection. These women all beneﬁt from
access to clinics such as the Cardiac Disease and Maternity
Clinic (CDMC), where multidisciplinary care contributes to the
likelihood of safe motherhood. In the future, echocardiography-
based screening of patients may further improve identiﬁcation
and referral of high-risk cases, although the cost-effectiveness of
this intervention is yet to be established.18 19 B-type natriuretic
peptides have also been shown to be effective biomarkers in
pregnant women, correlating with outcome,20 and need further
exploration as a bed-side test in the developing world.
LIMITATIONS
This study has several limitations as it is an observational study
conﬁned to a particular area. The data are therefore at variance
with the previously published literature. In addition, women
with subclinical disease, milder forms of CVD or fatal events
prior to admission were not captured. Only M-mode echocardi-
ography has been performed to qualify left ventricular function
in a number of cases. We have adhered to the published
STROBE guidelines relating to reporting of this type of study.21
CONCLUSION
Our data show a disease pattern in South Africa, markedly dif-
ferent to that of the developed world. Joint obstetric–cardiac
care is associated with excellent survival rates of mothers pre-
senting while pregnant, even with complex diseases, and their
offspring. The greatest risk of adverse outcome is attributable to
late presentation and left ventricular failure with death com-
monly occurring outside the 42-day maternal mortality report-
ing period. The perinatal outcome in an environment of
intensive surveillance and management was found to be gener-
ally good.
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Key messages
What is already known on this subject?
A number of registries on women with heart disease in
pregnancy have been reported in the past years. However, they
are predominantly from the developed world with a focus on
women presenting with operated congenital heart disease.
What might this study add?
We report on 225 women with heart disease in pregnancy. We
found a disease pattern markedly different to that in the
higher-income countries. Rheumatic heart disease,
cardiomyopathy and hypertensive heart failure are major
problems often complicated by HIV/AIDS as comorbidity.
How might this impact on clinical practice?
Joint obstetric–cardiac care showed survival rate of mothers
presenting while pregnant, even those with complex diseases
similar to that seen in the western world, but also that of their
offspring. However, high mortality occurred in the postpartum
period. As traditionally maternal mortality is reported as death
<42 days postdelivery, eight of nine deaths would have not
been recorded as maternal death, which could imply
underreporting of maternal deaths in the context of an overall
very high maternal death rate in South Africa.
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